Hypoparanoid - anxiety relating to calcium results

Nothing more endocrine than pondering over something so long that it doesn't matter any more! Well done!

I take it you are taking more time over your D&E application???

Attended the brilliant Reproductive Endocrinology meeting in London. Superb speakers and topics. Excited to put this new knowledge into practice! #endosky #medsky

The advances in hypopara management keep coming!

I really wish I could! That would be some paper. I haven't seen any convincing data either way. I worry a RCT would be impossible.

Can you provide a plot with mortality directly attributable to hyponatraemia?

It's my first Christmas as a consultant.

What do I get my amazing secretary?

#medsky

The slow-correcting heart failure patient will have higher mortality and a longer inpatient stay compared to the rapid-correcting patient with alcohol dependence and suppressed AVP. Their risks of ODS are not equivalent.

The omission of hypertonic saline strategies or hyponatraemia aetiologies limits it's utility. Not planning on changing my practice based on this paper having seen ODS first hand in rapid correctors.

You do wonder about how the pancreas copes with hypercalcaemia in PHP

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...

Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity

Only a single dose was administered - could a further dose at 6 months and/or BTM monitoring have mitigated the BMD loss?

Zoledronate Sequential Therapy to Prevent Bone Loss After Stopping Denosumab This randomized clinical trial examines the use of sequential therapy with zoledronate to prevent loss of bone mineral density after denosumab discontinuation in the first year.

Sequential zoledronic acid following densoumab did not prevent loss of lumbar spine BMD @jamacurrent.bsky.social